跳至主要内容
临床试验/NL-OMON56985
NL-OMON56985招募中不适用

Global Research Initiative for Patients Screening on MASH - GRIPonMASH

Julius Clinical0 个研究点目标入组 1,000 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
1,000

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - 18-75 year old;
  • - new or established diagnosis of at least 1 of the following 4 conditions:
  • type 2 diabetes mellitus, obesity, arterial hypertension or metabolic syndrome
  • (diagnostic criteria defined in protocol).

排除标准

  • - The patient is known with hepatitis B, C or HIV or any other liver condition
  • (like hemochromatosis, Wilson*s disease, sarcoidosis, etc);
  • - The patient is known with any other condition that may lead to liver fibrosis
  • or cirrhosis;
  • - The patient engages in (Excessive) alcohol use (defined as > 3 units/day in
  • males [30 grams/day] and > 2 units/day in females [20 grams/day]);
  • - The patient has a history or evidence of any other clinically significant
  • condition or planned or expected procedure that in the opinion of the
  • Investigator, may compromise the patient*s safety or ability to be included in
  • this study;
  • -The patient is an employee or contractor of the facility that is conducting
  • the study or is a family member of the Investigator, sub-Investigator, or any
  • Sponsor personnel;
  • - The patient is not able to understand the details of the protocol and/or is
  • not able to provide written informed consent;
  • - The patient is pregnant or breastfeeding.
  • - The patient underwent bariatric surgery in the last 12 months.

研究者

发起方
Julius Clinical

相似试验

尚未招募
3 期
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1Ewing Sarcoma
ACTRN12624000532505niversity of Birmingham900
进行中(未招募)
3 期
International clinical research programme to improve outcomes in newly diagnosed Ewing sarcoma – Trial 1Ewing SarcomaCancer
ISRCTN17938906niversity of Birmingham900
进行中(未招募)
1 期
A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Auraong term treatment of acute migraine, with or without aura, in children and adolescents, ages 12 to 17 years.MedDRA version: 12.0 Level: LLT Classification code 10066635 Term: Acute migraine
EUCTR2009-016375-30-NOMerck & Co., Inc.606
进行中(未招募)
1 期
A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Auraong term treatment of acute migraine, with or without aura, in children and adolescents, ages 12 to 17 years.MedDRA version: 12.0 Level: LLT Classification code 10066635 Term: Acute migraine
EUCTR2009-016375-30-BEMerck & Co., Inc.606
已完成
3 期
A Worldwide, Open Label, Clinical Trial to Examine the Long Term Safety and Tolerability of Rizatriptan in Pediatric Migraineurs for the Treatment of Migraine With or Without Auramigraine head ache10019231
NL-OMON34736Merck & Co., Inc.27